secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001193125-26-007063
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio reports $137.5M cash, appoints chair, gets $35.8M from warrants
---------------------------------------------------------------------

- Cash $137.5M at Dec 31, 2025, including $35.8M from Series B warrants; runway into Q2 2027.
- Full exercise of Series B warrants by Coastlands Capital, Frazier Life Sciences, and Gilead.
- Achieved milestone for masked antibody program under AbbVie; nominated CLDN18.2 T cell engager candidate.
- Appointed Sara Bonstein as board chair, succeeding Paul Clancy who retired Jan 6, 2026.
- Pipeline milestones: IND for XTX501 mid-2026, initial Phase 1 data H2 2027, STEAP1 candidate H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526007063/0001193125-26-007063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526007063/xlo-20260108.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-007063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer